REDWOOD CITY, Calif. — September 18, 2026
Corcept Therapeutics announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending European Commission approval of Lifyorli® (relacorilant) in combination with nab-paclitaxel for patients with platinum-resistant ovarian cancer. The recommendation is based on results from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, which demonstrated improved progression-free survival and overall survival for patients receiving relacorilant plus nab-paclitaxel compared with nab-paclitaxel alone. The European Commission is expected to issue a final decision in the fourth quarter of 2026.
ROSELLA Demonstrates Survival Benefits With Relacorilant
The pivotal ROSELLA Phase 3 trial enrolled 381 patients with platinum-resistant ovarian cancer across sites in the United States, Europe, South Korea, Brazil, Argentina, Canada and Australia. Patients were randomized 1:1 to receive relacorilant plus nab-paclitaxel or nab-paclitaxel alone. The trial demonstrated improvements in both progression-free survival and overall survival, supporting the CHMP recommendation and Corcept’s strategy of combining glucocorticoid receptor antagonism with chemotherapy in patients whose disease has become resistant to platinum-based treatment.
Relacorilant Targets Glucocorticoid Receptor Signaling
Relacorilant is a selective glucocorticoid receptor modulator designed to bind the glucocorticoid receptor without binding to the body’s other hormone receptors. Corcept is developing the therapy based on the role of cortisol and glucocorticoid receptor signaling in cancer biology. According to the company, cortisol can contribute to tumor growth and chemotherapy resistance while also suppressing immune responses. Relacorilant is currently marketed in the U.S. under the Lifyorli brand for platinum-resistant ovarian cancer and would expand its availability to European patients if appro
Advertisement
Corcept Advances Lifyorli Toward EU Approval
The CHMP recommendation represents the next regulatory milestone for Corcept’s selective glucocorticoid receptor modulation strategy in oncology. The company said the safety profile of relacorilant plus nab-paclitaxel in the Phase 2 and Phase 3 studies was consistent with the established safety profile of nab-paclitaxel monotherapy. Corcept continues to advance clinical programs involving cortisol modulation across solid tumors, hypercortisolism, ALS and liver disease, building on a research platform that includes more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. The European Commission’s final decision is anticipated in Q4 2026.
Source :Corcept Therapeutics press release
